Licensing Opportunities
Product
TOA EIYO has a powerful sales force that is able to penetrate into our focus market, providing appropriate medications in Japan.
We strongly believe and desire that our products can contribute to global human health.
Please contact us if you have an interest in introducing our products to countries other than Japan.
(Please see our products)
Research & Development Pipeline
In the cardiovascular field, we have several unique in-house NCEs and patch formulations through our research and development.
All of the products shown below are available for out-licensing, and we proactively seek out potential partners in all available territories.
Please contact us if you have an interest in our compounds.
| Product name(INN)/ Development code |
Formulation | Target indication | Available territory | Stage(in Japan) | |||||
|---|---|---|---|---|---|---|---|---|---|
| Pre clinical |
P1 | P2 | P3 | Launch | Status | ||||
| Bisoprolol / TY-0201 |
Patch | Hypertension | Any country (excl. China and Japan) |
Launched in 2013 | |||||
| Bisoprolol / TY-0201 |
Patch | Atrial Fibrillation | Any country (excl. China and Japan) |
Approved in 2019 (Expanded Indication) |
|||||
| Bisoprolol / TY-0201 |
Patch | Chronic HF | Any country (excl. China and Japan) |
Ongoing | |||||
HF:Heart Failure
Our Areas of Interest
TOA EIYO is seeking in-licensing opportunities for novel treatments/products that are able to address unmet medical needs or improve existing treatments in the following therapeutic areas in Japanese territory, preferably in the Phase II development stage or later, along with clarified POCs.
― Target of therapeutic areas (click to expand)
― Target development stage
・ Preclinical (Preparing for IND)
・ Ph1,Ph2,Ph3,application for approval,Launch
・ Preferably with evidence regarding POC or scientific evidence from clinical trials
― Target territories
・ Japan only
POC:Proof of Concept